Clinical Report: The Role of Platelets in Fatty Liver Disease Progression

Overview

This review highlights the significant role of platelets in the pathogenesis of metabolic dysfunction-associated steatohepatitis (MASH), emphasizing their involvement in inflammatory pathways and disease progression. Enhanced platelet activation correlates with disease severity and may serve as a non-invasive marker for monitoring MASH.

Background

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease linked to metabolic dysfunction, with potential progression to cirrhosis and hepatocellular carcinoma. Understanding the role of platelets in MASH is crucial, as they are implicated in inflammatory processes and liver injury. Recent studies suggest that platelet activation may be a key factor in the severity and progression of MASH.

Data Highlights

No numerical data or trial data provided in the article.

Key Findings

• Platelet activation is significantly elevated in patients with MASH compared to healthy individuals.
• Activated platelets release inflammatory mediators that contribute to liver injury and fibrosis.
• Patients with advanced MASH exhibit a hypercoagulable state, complicating clinical management.
• Platelet-derived microparticles and neutrophil extracellular traps amplify coagulation-inflammation crosstalk in the liver.
• Platelet-related markers may serve as non-invasive indicators for disease progression in MASH.

Clinical Implications

Clinicians should consider monitoring platelet activation and related markers in patients with MASH to assess disease severity and progression. Targeting platelet activity may offer therapeutic potential, warranting further investigation into antiplatelet strategies in conjunction with existing treatments.

Conclusion

Platelets play a pivotal role in the pathophysiology of MASH, influencing inflammatory and fibrotic processes. Further research is needed to elucidate the mechanisms of platelet-liver interactions and their implications for treatment.

References

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Clinical Research in Cardiology, 2020 -- Cardiovascular Implications of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review
3. Author(s)/Org, The Journal of Infectious Diseases, Year -- Decanoylcarnitine Improves Liver Mitochondrial Dysfunction in Hepatitis B Virus Infection by Enhancing Fatty Acid β-Oxidation
4. Author(s)/Org, Journal of Gastroenterology, Year -- Pathways Leading to Triglyceride Build-Up in Non-Alcoholic Fatty Liver Disease
5. American Gastroenterological Association, 2026 -- Introducing AGA’s new MASLD clinical care pathway
6. PubMed, 2025 -- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
7. Introducing AGA’s new MASLD clinical care pathway
8. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis - PubMed